# Jonathan D. Cheng

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jonathan-d-cheng/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,750 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 52 |
| i10-index | 100 |
| Last Known Institution | Princeton University |
| OpenAlex ID | https://openalex.org/A5112748795 |
| Works | 178 |

## Researcher papers

- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort](https://scholariq.org/papers/antitumor-activity-of-pembrolizumab-in-biomarker-unselected-patients-with/)
- [Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study](https://scholariq.org/papers/pembrolizumab-for-platinum-and-cetuximab-refractory-head-and-neck-cancer-results/)
- [Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer](https://scholariq.org/papers/immune-activation-and-response-to-pembrolizumab-in-pole-mutant-endometrial/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Princeton University](https://scholariq.org/institutions/princeton-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.